Mizuho Securities USA LLC Acquires 3,605 Shares of Humana Inc. (NYSE:HUM)

Mizuho Securities USA LLC boosted its stake in shares of Humana Inc. (NYSE:HUM) by 46.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,412 shares of the insurance provider’s stock after acquiring an additional 3,605 shares during the quarter. Mizuho Securities USA LLC’s holdings in Humana were worth $2,895,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pzena Investment Management LLC lifted its position in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares in the last quarter. Boston Partners raised its position in shares of Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after acquiring an additional 893,637 shares during the last quarter. FMR LLC lifted its stake in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Retirement Systems of Alabama boosted its holdings in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after acquiring an additional 192,801 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Humana in the third quarter worth about $50,102,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.37% of the company’s stock.

Humana Stock Performance

HUM opened at $271.65 on Tuesday. The company has a market capitalization of $32.79 billion, a price-to-earnings ratio of 27.30, a P/E/G ratio of 2.05 and a beta of 0.57. The business’s 50-day moving average price is $271.01 and its two-hundred day moving average price is $275.60. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Analyst Ratings Changes

Several brokerages have recently issued reports on HUM. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Finally, Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Eighteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.